Effect Of Mirtazapine On Lipids, Blood Glucose Metabolism Of Depressive Disorder With Diabetes | | Posted on:2015-01-22 | Degree:Master | Type:Thesis | | Country:China | Candidate:H Q Wei | Full Text:PDF | | GTID:2284330431992604 | Subject:Mental illness and mental hygiene | | Abstract/Summary: | PDF Full Text Request | | Effect of mirtazapine on serum lipid of depressive disorderwith type2diabetesObjective:To explore the effect of mirtazapine on lipid metabolism of depressive patientswith type2diabetes.Methods:Total90moderate depressive patients with type2diabetes were randomlydivided into three groups: mirtazapine (30–45mg/d) group, sertraline (125–200mg/d)group, and psychotherapy (for1to2times weekly cognitive therapy) group,30foreach. Three groups would all have12-week treatment. The fasting bloodglucose(FBG) of each group was measured at baseline. The total cholesterol(TC) orthe triglyceride (TG) of each group was measured at baseline and at week4,8and12of treatment for comparison.Results:1.Mirtazapine, sertraline and psychotherapy group had3,1or4case being off,respectively.2. Throughout the treatment period,the TC of mirtazapine group had statisticaldifference compared with the sertraline group and psychotherapy group respectively(P=0.030,P=0.016), while there was no statistical difference between the sertralinegroup and psychotherapy group(P=1.000).3. Compared with each other among three groups, The TG had no statisticaldifference (P>0.05). 4.The increased rates of TC among three groups had statistical different at week12(χ2=7.253,P=0.027),and the95%confidence interval of the population rate was0%to3.0%. The increased rate of mirtazapine group was the highest, and the rateincreased gradually with the treatment points.5.The TG of mirtazapine group had no statistical difference between at baselineand at week4ã€8or12(P>0.05).6.The influence of duration of diabetes, age, and HAMD-24score on thebaseline total cholesterol was statistical different(P<0.05),and the influence ofduration of diabetes, age on the baseline triglyceride was statistical different also(P<0.05).Conclusions:1.Mirtazapine treatment of moderate depressive patients with type2diabetes canlead to elevated levels of serum total cholesterol,and the increased rate of TC risedgradually with the treatment time.2.The effect on serum triglyceride levels in these patients who were treated bymirtazapine were no significant.3.Duration of diabetes, age, and HAMD-24score can be used as predictors ofvariation in total cholesterol not being interfered levels.4.Duration of diabetes, age can be used as predictors of variation in triglyceridenot being interfered levels. Effect of mirtazapine on blood glucose of depressivedisorder with type2diabetesObjective:To explore the effect of mirtazapine on fasting blood glucose(FBG) ofdepressive patients with type2diabetes.Methods:Total78moderate depressive patients with type2diabetes were randomlydivided into three groups: mirtazapine (30–45mg/d) group, sertraline (150–200mg/d)group, and psychotherapy (cognitive therapy once or twice a week) group,29foreach. Each group have a12-week treatment. The FBG were measured at baseline andat wk4,8and12of treatment for comparison.Results:1.Mirtazapine, sertraline and psychotherapy group had3,3or1case being off,respectively.2. Throughout the treatment period,the FBG of mirtazapine group had statisticaldifference compared with the sertraline group and psychotherapy group respectively(P<0.05,P<0.01), while there was no difference between the sertraline group andpsychotherapy group(P>0.05).3.The FBG of the three groups had no statistical difference between at baselineand at wk4(P>0.05), while there was statistical difference in FBG between atbaseline and at wk8or12(P <0.01).4.The abnormally increased rates of FBG among the three groups had nostatistical difference at week4or8(Pï¼0.996or Pï¼0.631), while it was statisticaldifferent among the three groups at week12(P=0.018),and the95%confidenceinterval of the population rate is1.5%to2.0%.Conclusions:1.The abnormal rise of FBG with clinical significance can occur among moderate depressive patients with type2diabetes who were treated by mirtazapine.2.The abnormally increased rate of FBG occurred among moderate depressive patientswith type2diabetes who were treated by mirtazapine may have a time tendency. | | Keywords/Search Tags: | mirtazapine, depression, diabetes mellitus, type2, total cholesterol, triglyceridemirtazapine, blood glucose | PDF Full Text Request | Related items |
| |
|